[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100613697":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":54,"collaborators":20,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":60,"sex":66,"minAge":67,"maxAge":20,"enrollmentInfo":68,"targetDuration":20,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":79,"overallStatus":44,"whyStopped":20,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Technical University of Munich","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"at home tdcs after ECT, rTMS or Esketamine treatment","ACTIVE_COMPARATOR","Transcranial Direct Current Stimulation (tDCS) at home, 20 sessions, 2mA (5 days\u002Fweek, for 4 weeks) as at home maintenance treatmentafter successfull ECT, rTMS or Esketamine treatment.",[13],"Device: tDCS",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","tDCS","Description: Transcranial Direct Current Stimulation delivered at an intensity of 2 mA over electrodes at F3\u002FF4 (bifrontal, over DLPFC), for 30 minutes a day, Monday to Friday, for a total 20 sessions.",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Ulrike Vogelmann, Dr. med.","CONTACT","+4917661535471","ulrike.vogelmann@mri.tum.de",[28,42],{"facility":29,"status":30,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":20},"Technical University of Munich, TUM School of Medicine and Health, Department of Psychiatry and Psychotherapy, Munich,","ENROLLING_BY_INVITATION","München","Bavaria","81675","Germany","DE",{"type":37,"coordinates":38},"Point",[39,40],13.46314,48.69668,{"lat":40,"lon":39},{"facility":43,"status":44,"city":31,"state":20,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":45,"geoPoint":49,"contacts":50},"Department of Psychiatry and Psychotherapy, Technical University of Munich, University Hospital","RECRUITING",{"type":37,"coordinates":46},[47,48],13.31243,51.60698,{"lat":48,"lon":47},[51],{"name":52,"role":24,"phone":53,"phoneExt":20,"email":26},"Ulrike Vogelmann, MD","+498941406882",{"type":55,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"PRINCIPAL_INVESTIGATOR","Ulrike Vogelmann","Dr.med.","100613697","at-home-tdcs-as-maintenance-therapy-100613697",false,"NCT07269964","At-Home tDCS as Maintenance Therapy","At-home tDCS as Maintenance Therapy Following Successful Treatment With rTMS, ECT, and Esketamine - A Pilot Study","MaintenanceDC","Inclusion Criteria:\n\n* Adults (≥18 years).\n* Diagnosis according to ICD-10: recurrent depressive disorder, severe depressive disorder, schizoaffective disorder (depressive episode) or bipolar affective disorder (depressive episode).\n* Clear indication for maintenance therapy after successful acute treatment (esketamine, rTMS, or ECT) with remission\u002Fimprovement of symptoms.\n* Capacity to provide informed consent, confirmed in a physician-led consent discussion.\n\nExclusion Criteria:\n\n* Currently in the acute treatment phase of an affective disorder and non-response to previous treatments.\n* Currently clinically relevant Axis II disorders.\n* Suicidal risk, including suicidal ideation.\n* Contraindications for tDCS: e.g., skin disease at electrode sites, cochlear implants.\n* Neurological, somatic, or psychiatric comorbidities that could compromise validity or safety.","ALL","18 Years",{"count":69,"type":70},30,"ESTIMATED","INTERVENTIONAL",[73],"NA","The primary purpuse of this pilot study is to find out whether a home-based transcranial direct current stimulation (tDCS) program is feasible and well tolerated as maintenance therapy and whether there are early signs that it helps maintain the clinical clinical benefits achieved during successful acute inpatient treatment.\n\nParticipant population:\n\nAdults (18+) with depressive disorder who had already improved\u002Fstabilized after acute treatment at our clinic (esketamine, repetitive transcranial magnetic stimulation , or electroconvulsive therapy).\n\nMain questions:\n\nFeasibility: Do participants reliably complete the home program and stay in the study?\n\nPreliminary effectiveness: Do improvements of depressive symptoms hold up over the 4-week treatment and 2-week follow-up (based on self-report and clinician-rated scales)?\n\nParticipants receive standardized instruction from trained staff and a portable tDCS device (with cap and small sponge electrodes) and complete 20 home sessions over 4 weeks (5 per week), each 30 minutes at a very low current (2 mA); the device gently ramps current up\u002Fdown for comfort.\n\nDuring treatment, participants use a smartphone app with step-by-step guidance and reminders; sessions are automatically logged. They will also fill out short weekly self-rating questionnaires and join brief phone check-ins every 2 weeks.\n\nWhere:\n\nDepartment and Outpatient Clinic of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technical University of Munich\n\nSafety \\& data privacy:\n\nThe device monitors electrode contact and pauses automatically if contact is poor. Typical sensations can include mild tingling or redness. The app stores anonymized session data so the care team can track progress; no personal data are exchanged between the app and the stimulator, and access is via a secure clinical portal.",[76,77,78],"MDD","Severe Depression","Major Depressive Episode",[80,17,81,82,83],"Non Invasive Brain Stimulation (NIBS)","at-home treatment","tdcs at home","transcranial direct current stimulation","2025-11-25",{"date":86,"type":87},"2025-12-08","ACTUAL",{"date":89,"type":87},"2024-10-01",{"date":91,"type":70},"2026-11-29",{"name":5,"class":6},2]